ALX ONCOLOGY HOLDINGS

ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia

12 ديسمبر 2022 10:00:00 بحسب Nasdaq GlobeNewswire

ALX Oncology Appoints Scott Garland to its Board of Directors

29 نوفمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

08 نوفمبر 2022 16:01:00 بحسب Nasdaq GlobeNewswire

ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting

03 نوفمبر 2022 09:00:01 بحسب Nasdaq GlobeNewswire

ALX Oncology Announces Upcoming Investor Conference Participation

02 نوفمبر 2022 07:00:01 بحسب Nasdaq GlobeNewswire

ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept

31 أكتوبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

05 أكتوبر 2022 08:01:00 بحسب Nasdaq GlobeNewswire

ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

21 سبتمبر 2022 16:01:00 بحسب Nasdaq GlobeNewswire

ALX Oncology Announces Upcoming Investor Conference Participation

01 سبتمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer

15 أغسطس 2022 07:00:01 بحسب Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer

11 أغسطس 2022 07:00:02 بحسب Nasdaq GlobeNewswire

ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

08 أغسطس 2022 16:01:00 بحسب Nasdaq GlobeNewswire

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia

29 يونيو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

ALX Oncology Announces Evorpacept Clinical Program Updates

03 يونيو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference

01 يونيو 2022 07:00:02 بحسب Nasdaq GlobeNewswire

ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

09 مايو 2022 16:01:00 بحسب Nasdaq GlobeNewswire

ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors

12 أبريل 2022 07:00:01 بحسب Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer

02 مارس 2022 07:00:01 بحسب Nasdaq GlobeNewswire

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer

27 يناير 2022 17:51:25 بحسب Nasdaq GlobeNewswire

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022

10 يناير 2022 06:00:00 بحسب Nasdaq GlobeNewswire